P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H1 2016

P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H1 2016
Published Jun 28, 2016
59 pages — Published Jun 28, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H1 2016, provides in depth analysis on P2X Purinoceptor 3 (P2RX3) targeted pipeline therapeutics.

The report provides comprehensive information on the P2X Purinoceptor 3 (P2RX3) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for P2X Purinoceptor 3 (P2RX3)
- The report reviews P2X Purinoceptor 3 (P2RX3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics and enlists all their major and minor projects
- The report assesses P2X Purinoceptor 3 (P2RX3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to P2X Purinoceptor 3 (P2RX3) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for P2X Purinoceptor 3 (P2RX3)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifyin

  
Source:
Document ID
GMDHC0155TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables41
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
P2X Purinoceptor 3 (P2RX3) Overview71
Therapeutics Development83
  P2X Purinoceptor 3 (P2RX3) Products under Development by Stage of Development81
  P2X Purinoceptor 3 (P2RX3) Products under Development by Therapy Area91
  P2X Purinoceptor 3 (P2RX3) Products under Development by Indication101
P2X Purinoceptor 3 (P2RX3) Pipeline Products Glance112
  Late Stage Products112
P2X Purinoceptor 3 (P2RX3) Products under Development by Companies132
P2X Purinoceptor 3 (P2RX3) Products under Development by Universities/Institutes152
P2X Purinoceptor 3 (P2RX3) Therapeutics Assessment175
  Assessment by Monotherapy/Combination Products171
  Assessment by Mechanism of Action181
  Assessment by Route of Administration191
  Assessment by Molecule Type202
P2X Purinoceptor 3 (P2RX3) Companies Involved in Therapeutics Development226
  Afferent Pharmaceuticals, Inc.221
  Asana BioSciences, LLC231
  Integral Molecular, Inc.241
  Neurim Pharmaceuticals Ltd251
  Pfizer Inc.261
  Shionogi &Co., Ltd.271
P2X Purinoceptor 3 (P2RX3) Drug Profiles2814
  AF-130 Drug Profile281
  AF-219 Drug Profile294
  ASN-009 Drug Profile331
  Monoclonal Antibodies to Antagonize P2X3 Receptor for Pain Drug Profile341
  Monoclonal Antibody to Antagonize P2X2 and P2X3 for Visceral Pain Drug Profile351
  NEO-5937 Drug Profile361
  OSX-300 Drug Profile371
  OSX-300 Backups Drug Profile381
  piromelatine Drug Profile392
  Small Molecule to Antagonize P2X3 Receptor for Hyperalgesia Drug Profile411
P2X Purinoceptor 3 (P2RX3) Dormant Projects422
P2X Purinoceptor 3 (P2RX3) Discontinued Products441
P2X Purinoceptor 3 (P2RX3) Featured News &Press Releases4513
  May 18, 2016: Afferent Pharmaceuticals Reports Cardiovascular Research Showing P2X3 Antagonism Successfully Reduces Hypertension By Restoring Autonomic Nervous Balance at the 2016 American Thoracic Society Conference451
  May 16, 2016: Afferent Pharmaceuticals Presents Updated Positive Results with AF-219 from Phase 2B Chronic Cough Study at the 2016 American Thoracic Society International Conference462
  Apr 25, 2016: Afferent Pharmaceuticals Announces Presentation of Chronic Cough Clinical Data at the Upcoming American Thoracic Society 2016 International Conference481
  Apr 25, 2016: Afferent Pharmaceuticals Announces Presentation of Hypertension Research at the Upcoming American Thoracic Society 2016 International Conference491
  Dec 08, 2015: Afferent Pharmaceuticals Advances Novel Molecule, AF-130, to Phase 1 Clinical Trial491
  Nov 11, 2015: Afferent Pharmaceuticals Announces Phase 2 Clinical Trial with AF-219 in Cough in Idiopathic Pulmonary Fibrosis (IPF) Patients501
  Sep 28, 2015: Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial511
  Feb 26, 2015: Afferent Clinical Data for Lead Candidate, AF-219, Demonstrate Improvements in Pain and Urinary Urgency in Interstitial Cystitis / Bladder Pain Syndrome521
  Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet531
  Sep 09, 2013: Afferent Pharmaceuticals Reports Positive Phase 2 Clinical Data for the Company s Lead P2X3 Antagonist, AF-219541
  Feb 18, 2013: Neurim Pharma Announces Positive Phase II Clinical Trial Results Of Piromelatine For Treatment Of Insomnia551
  Jul 24, 2011: Neurim Announces Positive Results From Phase I And Phase Ib Clinical Trials With Neu-P11561
  Aug 25, 2010: Afferent Reports Data Supporting Potential Utility Of P2X3 Antagonists In Lowering Bladder Reflexes571
Appendix582
  Methodology581
  Coverage581
  Secondary Research581
  Primary Research581
  Expert Panel Validation581
  Contact Us581
  Disclaimer591

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H1 2016" Jun 28, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/P2X-Purinoceptor-3-P2RX3-Pipeline-Review-H1-2016-2088-16052>
  
APA:
Global Markets Direct - Market Research. (2016). P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H1 2016 Jun 28, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/P2X-Purinoceptor-3-P2RX3-Pipeline-Review-H1-2016-2088-16052>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.